Matthew R. Henn files SEC Form 4 disclosures for Seres Therapeutics, Inc.. They have made 1 open-market trade across 1 company since 2020, most recently 2025-02-18.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| MCRB | 88,396 | $218K |
Shares reported on the most recent Form 4, priced at the 2025-02-19 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MCRB | SELL · 10b5-1 | 2025-02-18 | 2025-02-19 | $0.81 | $3K | -8.7% | -13.2% | -49.8% |
| MCRB | SELL · 10b5-1 | 2024-11-18 | 2024-11-19 | $0.54 | $501 | +35.8% | +34.9% | +21.8% |
| MCRB | SELL · 10b5-1 | 2024-10-28 | 2024-10-29 | $0.69 | $3K | -5.4% | +29.7% | +11.4% |
| MCRB | SELL · 10b5-1 | 2024-08-16 | 2024-08-19 | $0.84 | $775 | -13.4% | +15.1% | -36.5% |
| MCRB | SELL · 10b5-1 | 2024-05-15 | 2024-05-17 | $0.94 | $838 | +6.4% | -26.7% | -3.3% |
| MCRB | SELL · 10b5-1 | 2024-02-16 | 2024-02-16 | $1.08 | $5K | +5.6% | -29.8% | -14.4% |
| MCRB | SELL · 10b5-1 | 2023-10-30 | 2023-10-31 | $1.35 | $5K | -32.8% | -31.1% | -17.2% |
| MCRB | SELL | 2020-12-01 | 2020-12-03 | $27.04 | $5.0M | +2.7% | +0.0% | -29.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.